0OB3 Stock Chart & Stats
€2.10
€0.05(2.18%)
At close: 4:00 PM EDT
€2.10
€0.05(2.18%)
Day’s Range― - ―
52-Week Range€2.03 - €5.42
Previous CloseN/A
Volume143.00
Average Volume (3M)106.96K
Market Cap
€407.36M
Enterprise Value€589.53
Total Cash (Recent Filing)€105.27M
Total Debt (Recent Filing)€209.50M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Aug 13, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding189,771,240
10 Day Avg. Volume86,772
30 Day Avg. Volume106,960
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)5.89
Price to Sales (P/S)3.58
P/FCF Ratio-10.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.39
Revenue Forecast (FY)€152.15M
Bulls Say, Bears Say
Bulls Say
Breakthrough Lyme Vaccine (VLA15)VLA15's Phase III efficacy (>70%) and planned Pfizer regulatory submissions create a durable commercial opportunity. As a near-unique candidate with a partner able to execute regulatory filings and commercialization, this materially increases odds of a lasting, high-margin product revenue stream once approved.
Manufacturing & Market-access ProgressConcrete in-market execution (Brazil pilot, Butantan licensure) and completed manufacturing transfers outside the U.S. reduce scale-up risk and support regional supply. These durable manufacturing and local-partnership advances improve access, revenue diversification and reduce reliance on a single facility long-term.
Restructuring And Liquidity ActionsA sizable opex reduction program and recent financing materially extend runway and improve operating leverage if executed. Lower structural cost base combined with available cash and financing reduces near-term dilution risk and supports focused investment in priority programs over the coming months.
Bears Say
Sustained Cash Burn And Negative Cash FlowPersistent negative operating and free cash flow indicate the business is consuming cash, forcing ongoing reliance on external financing. Over a 2–6 month horizon this constrains flexibility to fund manufacturing scale-up, regulatory filings, or commercial launches without further dilution or debt.
Sharp Revenue Decline And Margin DeteriorationA steep revenue drop and large gross-margin compression reflect weaker travel-vaccine demand and one-off manufacturing costs. These trends undermine durable profitability and reduce cash generation potential, making it harder to fund R&D and commercialization absent structural demand recovery or sustained cost cuts.
Elevated Leverage And Balance-sheet StrainHigh leverage with a shrinking equity base increases refinancing and dilution risk, especially amid cash burn and weaker earnings. Over several months this raises the probability management must prioritize liquidity measures or asset-light partnering over organic investment, constraining strategic optionality.
Valneva News
0OB3 FAQ
What was Valneva SE’s price range in the past 12 months?
Valneva SE lowest share price was €2.03 and its highest was €5.42 in the past 12 months.
What is Valneva SE’s market cap?
Valneva SE’s market cap is €407.36M.
When is Valneva SE’s upcoming earnings report date?
Valneva SE’s upcoming earnings report date is Aug 13, 2026 which is in 7 days.
How were Valneva SE’s earnings last quarter?
Valneva SE released its earnings results on May 13, 2026. The company reported -€0.18 earnings per share for the quarter, missing the consensus estimate of -€0.063 by -€0.117.
Is Valneva SE overvalued?
According to Wall Street analysts Valneva SE’s price is currently Overvalued.
Does Valneva SE pay dividends?
Valneva SE does not currently pay dividends.
What is Valneva SE’s EPS estimate?
Valneva SE’s EPS estimate is -0.08.
How many shares outstanding does Valneva SE have?
Valneva SE has 189,771,240 shares outstanding.
What happened to Valneva SE’s price movement after its last earnings report?
Valneva SE reported an EPS of -€0.18 in its last earnings report, missing expectations of -€0.063. Following the earnings report the stock price went down -0.311%.
Which hedge fund is a major shareholder of Valneva SE?
Currently, no hedge funds are holding shares in GB:0OB3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valneva SE
Valneva SE is a specialized biotechnology company focused on developing and bringing to market preventative vaccines for infectious diseases with significant unmet medical needs. Their commercial offerings for travelers include IXIARO, a vaccine against Japanese encephalitis, and DUKORAL, an oral vaccine designed to protect against diarrhea caused by Vibrio cholera and specific heat-labile toxin-producing Enterotoxigenic Escherichia coli. The company also progressed VLA2001, a vaccine candidate targeting SARS-CoV-2. In its development pipeline, Valneva has VLA15, a Lyme disease vaccine candidate that has concluded Phase II clinical trials, and VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III evaluation. The company distributes its products across the United States, Canada, various European nations including Germany, Austria, the Nordics, and the United Kingdom, as well as other global markets. Valneva SE has established strategic partnerships, notably with Pfizer, Inc. for the joint development and commercialization of its Lyme disease vaccine, and with Instituto Butantan for the creation, manufacturing, and marketing of a single-shot chikungunya vaccine. The company was established in 1998 and operates from its headquarters in Saint-Herblain, France.